Sign inJoin waitlistJoin the waitlist

Alexandra Drakaki

Medical Director, Genitourinary Oncology Program · UCLA David Geffen School of Medicine/UCLA Medical Center

Credentials: · · · · · · ·

History

Genitourinary Oncology Program · UCLA David Geffen School of Medicine/UCLA Medical Center
Present
Genitourinary Oncology Program · UCLA
Present
GU Oncology Program · David Geffen School of Medicine at UCLA
Present

Dana Farber Cancer Center Harvard Medical School
2013–2014
Beth Israel Deaconess Medical Center
2010–2013
Internal Medicine
St. Elizabeth's Medical Center
2007–2010
Boston Children's Hospital
2006–2009
University of Crete School of Medicine
2002–2006

Research

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
The Lancet · 2017 · 1,812 citations
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
New England Journal of Medicine · 2024 · 923 citations
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Journal of Clinical Oncology · 2016 · 673 citations

Allan Pantuck
31 papers
Karim Chamie
24 papers
Petros Grivas
21 papers
Izak Faiena
18 papers · 16 as a fellow
Evan Yu
17 papers
GS
Guru Sonpavde
15 papers
SL
Sandy Liu
15 papers · 1 as a fellow
Ali Khaki
14 papers · 2 as a fellow
Andrew Lenis
14 papers · 14 as a resident
Pedro Barata
14 papers
Yousef Zakharia
14 papers · 2 as a fellow
Amirali Salmasi
13 papers

Clinical trials

Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
Principal investigator · Completed · Phase 1
Jonsson Comprehensive Cancer Center
2013–2021
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2033
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Site PI · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2024–2030
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Site PI · Recruiting · Phase 2
Acrivon Therapeutics
2022–2027